Search

Showing "11155" results for ""

New CCR5 antagonist TBR-652 shows good antiviral activity in early study

Increased testing leads to decrease in viral load and infections in San Francisco, and in late diagnosis in Washington

Elvitegravir 'Quad' pill performs well, new booster cobicistat works as well as ritonavir

Overall HIV prevalence stabilises at 11% in South Africa, with decreases in younger age groups

Once-daily darunavir effective and less toxic than twice-daily in experienced patients without prior darunavir resistance: ODIN

CCR5 antagonist vicriviroc fails to surpass potent background regimen

French gay men face sixtyfold HIV risk: incidence increasing in Netherlands

ACTG 5202: No significant difference in time to failure between Kivexa and Truvada in patients with lower viral loads when paired with efavirenz or atazanavir

Maraviroc showing tantalising promise as microbicide in preclinical studies

One-quarter died on HIV treatment waiting list in South Africa's Free State province

Smoking cessation lowers cardiovascular risk in D:A:D cohort

Vitamin D deficiency extremely common among HIV-positive patients in diverse regions

Treatment drive in British Columbia produces modest declines in diagnoses and viral loads

Immune restoration in DART study: late start means low CD4 count for years

More evidence supports isoniazid for TB prevention in people with HIV

HIV treatment may prevent at least nine out of ten transmissions

Chemotherapy plus ART best treatment for Kaposi's sarcoma in South African study

Most neurosyphilis is caused by one specific strain

Receive the latest HIV research and conference news

Showing "11155" results for ""

New CCR5 antagonist TBR-652 shows good antiviral activity in early study

Increased testing leads to decrease in viral load and infections in San Francisco, and in late diagnosis in Washington

Elvitegravir 'Quad' pill performs well, new booster cobicistat works as well as ritonavir

Overall HIV prevalence stabilises at 11% in South Africa, with decreases in younger age groups

Once-daily darunavir effective and less toxic than twice-daily in experienced patients without prior darunavir resistance: ODIN

CCR5 antagonist vicriviroc fails to surpass potent background regimen

French gay men face sixtyfold HIV risk: incidence increasing in Netherlands

ACTG 5202: No significant difference in time to failure between Kivexa and Truvada in patients with lower viral loads when paired with efavirenz or atazanavir

Maraviroc showing tantalising promise as microbicide in preclinical studies

One-quarter died on HIV treatment waiting list in South Africa's Free State province

Smoking cessation lowers cardiovascular risk in D:A:D cohort

Vitamin D deficiency extremely common among HIV-positive patients in diverse regions

Treatment drive in British Columbia produces modest declines in diagnoses and viral loads

Immune restoration in DART study: late start means low CD4 count for years

More evidence supports isoniazid for TB prevention in people with HIV

HIV treatment may prevent at least nine out of ten transmissions

Chemotherapy plus ART best treatment for Kaposi's sarcoma in South African study

Most neurosyphilis is caused by one specific strain

Receive the latest HIV research and conference news